The pharmaceutical industry is bracing for chaos if President Trump follows through on his threat to impose “a major tariff” ...

Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

Robert Scott Wilson, who plays the role of Alex on the daytime drama, recently shared his thoughts on the storyline and how his character feels momentarily relieved about not having a child on the ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

A Telling Lie: Robert Scott Wilson plays Alex’s relief over Joy saying she’s not pregnant as Stephanie (Abigail Klein) stands by him. As a big fan of the Alex and Stephanie pairing on Days of ...

Robert Scott Wilson (Alex), who worked closely with Hopkins during her months on the show, tells Soap Opera Digest that he was sorry to see Hopkins leave. “She was fantastic. She is fantastic, ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

SO IT WAS, IT HAD TO HAPPEN EVENTUALLY. BUT IT IS WILD TO THINK OF ANKENY CENTENNIAL WITHOUT BOB FONTANA AND SCOTT DEYOUNG, LIFELONG TEACHERS AND COACHES SYNONYMOUS WITH ANKENY. FROM THE TIME I ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a cash and debt-free basis, it said on Monday. The deal includes an initial ...